Medication for cardiovascular disease
Pro Research Analysisby 
Searched over 200M research papers
Medication for Cardiovascular Disease: A Comprehensive Overview
Traditional Chinese Medication for Cardiovascular Disease
Efficacy and Safety of Traditional Chinese Medication (TCM)
Traditional Chinese medication (TCM) is increasingly utilized for treating cardiovascular disease (CVD) in China and other Asian countries. Despite its popularity, the therapeutic efficacy and adverse effects of TCM are challenging to evaluate due to the limited number of large-scale, randomized controlled trials (RCTs). A review of 68 RCTs involving 16,171 patients indicated that TCM is associated with significant improvements in surrogate endpoints for hypertension, coronary heart disease, cardiac arrhythmias, and heart failure. Importantly, the risk of adverse effects was not higher compared to no intervention, placebo, or Western medications. However, the effectiveness of TCM in reducing all-cause or cardiovascular mortality remains uncertain and requires further large-scale RCTs .
Access to Cardiovascular Medications in Low- and Middle-Income Countries
Barriers and Strategies for Improving Access
Cardiovascular diseases represent the highest burden of disease globally, and access to medications is crucial for prevention and treatment. In low- and middle-income countries, multiple barriers hinder access to CVD medications, including low availability in healthcare facilities, high out-of-pocket costs, and poor medication adherence. Strategies to improve access include providing medicines at lower costs, ensuring quality, promoting appropriate use, and managing intellectual property issues. Fixed-dose combinations have shown positive effects on adherence and intermediate outcomes like blood pressure and cholesterol levels. Efficient procurement of low-cost, quality-assured generic medicines and insurance schemes that waive copayments for long-term medications are promising strategies to enhance access .
Adherence to Cardiovascular Medications
Impact of Adherence on Outcomes
Adherence to cardiovascular medications is vital for the secondary prevention of coronary arterial disease (CAD). Real-world evidence suggests that optimal adherence significantly influences the absolute and relative risks of mortality in patients with CAD. Poor adherence is a major issue, with approximately 9% of CVD cases in the EU attributed to non-adherence to vascular medications. Interventions to improve adherence, such as mobile phone-based interventions, have shown mixed results. Some trials reported small benefits in reducing blood pressure and cholesterol levels, while others found no significant effects. Overall, there is low-quality evidence on the effectiveness of these interventions, highlighting the need for further research Chen2022Palmer2018Ogungbe2020.
Glucose-Lowering Medications and Cardiovascular Outcomes
Associations and Evidence Strength
Given the global burden of diabetes and its association with CVD, understanding the cardiovascular safety of glucose-lowering medications is crucial. An umbrella review of 232 meta-analyses evaluated ten classes of diabetes drugs, identifying six risk and 38 protective associations with cardiovascular outcomes. Some drugs, like glimepiride and rosiglitazone, were associated with increased risks of stroke and heart failure, respectively. Conversely, glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors showed significant protective effects against major adverse cardiovascular events, cardiovascular death, myocardial infarction, stroke, and heart failure. These findings underscore the importance of selecting appropriate glucose-lowering medications to mitigate cardiovascular risks .
New and Emerging Cardiovascular Drugs
Innovations in Treatment
Despite the availability of several effective cardiovascular drugs, the need for new treatments remains due to the incomplete success in managing CVD and hypertension. Recent developments include new chemical entities with different mechanisms of action, showing promise in treating hypertension, CVD, heart failure, stroke, and type 2 diabetes mellitus. These emerging drugs can be used alone or in combination with existing medications, potentially improving treatment outcomes and reducing the socioeconomic impact of CVD .
Conclusion
The management of cardiovascular disease involves a multifaceted approach, including traditional and modern medications, strategies to improve access and adherence, and the development of new drugs. While traditional Chinese medication shows promise, its efficacy in reducing mortality needs further investigation. Improving access to cardiovascular medications in low- and middle-income countries and enhancing adherence through innovative interventions are critical steps. Additionally, selecting appropriate glucose-lowering medications and exploring new treatment options can significantly impact cardiovascular outcomes. Continued research and systematic approaches are essential to optimize the prevention and treatment of cardiovascular disease globally.
Sources and full results
Most relevant research papers on this topic